Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial
David E Spaner, Guizhei Wang, Lindsay McCaw, Yanmei Li, Patricia Disperati, Mary-Ann Cussen, Yonghong Shi, David E Spaner, Guizhei Wang, Lindsay McCaw, Yanmei Li, Patricia Disperati, Mary-Ann Cussen, Yonghong Shi
No abstract availableKeywords: Ibrutinib; Janus Kinases; Kinase inhibitors; Ruxolitinib; STAT3; chronic lymphocytic leukemia; phosphoproteome.
Figures
Source: PubMed